Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
June 03 2021 - 4:45PM
via NewMediaWire -- Neovasc Inc. (“
Neovasc”
or the “
Company”) (NASDAQ, TSX: NVCN) is pleased
to announce the results of the votes on matters considered at its
Annual General Meeting of Shareholders held on June 3, 2021 in
Vancouver, B.C. (the “
Meeting”).
At the Meeting, the shareholders of the Company (the
“Shareholders”) re-elected board members Steven
Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko and Fred
Colen to serve in office until the next annual meeting or until
their successors are duly elected or appointed. Detailed results of
the voting in respect of the election of directors are as
follows:
Nominee |
Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld |
Steven Rubin |
6,318,465 |
94.48% |
369,431 |
5.52% |
Paul Geyer |
6,410,453 |
95.85% |
277,431 |
4.15% |
Doug Janzen |
6,332,243 |
94.68% |
355,653 |
5.32% |
Norman Radow |
6,410,462 |
95.85% |
277,434 |
4.15% |
Alexei Marko |
6,320,514 |
94.51% |
367,382 |
5.49% |
Fred Colen |
6,174,668 |
92.33% |
513,228 |
7.67% |
At the Meeting, the Shareholders also approved the unallocated
options under the Company’s stock option plan (90.49% of votes cast
in favour) and re-appointed Grant Thornton LLP, Chartered
Accountants as auditors of the Company.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially
available in the United States and has been commercially available
in Europe since 2015, and TiaraTM for the transcatheter treatment
of mitral valve disease, which is currently under clinical
investigation in the United States, Canada, Israel and Europe. For
more information, visit: www.neovasc.com
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@icrinc.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and applicable Canadian securities
laws that may not be based on historical fact. When used herein,
the words "expect", "anticipate", "estimate", "may", "will",
"should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements may involve but are not limited to, expectations as to
the growing cardiovascular marketplace. Forward-looking statements
are based on estimates and assumptions made by the Company in light
of its experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company's actual
results, performance or achievements to differ materially from
those expressed or implied by the forward looking statements,
including those described in the "Risk Factors" section of the
Company's Annual Information Form and in the Management's
Discussion and Analysis for the three months ended March 31, 2021
(copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company's forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2023 to Jul 2024